Article
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
The Journal of pharmacology and experimental therapeutics - 1 Aug 1999
Ibeanu G C, Blaisdell J, Ferguson R J, Ghanayem B I, Brosen K, Benhamou S, Bouchardy C, Wilkinson G R, Dayer P, Goldstein J A
Abstract excerpt
Cytochrome P-450 (CYP) 2C19 is responsible for the metabolism of a number of therapeutic agents such as S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Genetic polymorphisms in this enzyme are responsible for the poor metabolizers (PM) of mephenytoin, which represent approximately 13-23% of Asians and 3-5% of Caucasians. Several polymorphisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.